Compare ENTA & MYN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ENTA | MYN |
|---|---|---|
| Founded | 1995 | 1992 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance Companies |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 374.6M | 380.1M |
| IPO Year | 2012 | N/A |
| Metric | ENTA | MYN |
|---|---|---|
| Price | $12.50 | $9.61 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $20.40 | N/A |
| AVG Volume (30 Days) | 143.3K | ★ 181.3K |
| Earning Date | 05-11-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 4.12% |
| EPS Growth | ★ 29.93 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $102,814,000.00 | N/A |
| Revenue This Year | $7.76 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 16.48 | N/A |
| 52 Week Low | $4.09 | $9.13 |
| 52 Week High | $17.15 | $10.26 |
| Indicator | ENTA | MYN |
|---|---|---|
| Relative Strength Index (RSI) | 44.54 | 34.67 |
| Support Level | $12.09 | $9.14 |
| Resistance Level | $15.52 | $9.63 |
| Average True Range (ATR) | 0.78 | 0.10 |
| MACD | -0.07 | -0.04 |
| Stochastic Oscillator | 36.00 | 28.95 |
Enanta Pharmaceuticals Inc is a biotechnology company that uses a chemistry-based drug discovery approach to develop small-molecule candidates for virology and immunology applications. It focuses on Virology and Immunology. Its active development programs in virology are focused on respiratory syncytial virus, or RSV, and SARS-CoV-2, and Hepatitis B virus. In immunology, the company is engaged in designing and developing potent and selective, oral small molecule inhibitors for the treatment of type 2 inflammatory disease. The company has collaborated with AbbVie, which markets its protease inhibitor paritaprevir, with additional inhibitors in development. The company generates the majority revenue in the form of royalty revenue.
Blackrock Muniyield NY Quality FD, Inc is a closed-end management investment company. Its objective is to provide shareholders with a high level of current income exempt from federal income taxes. The Fund invests in long-term municipal obligations that are investment grade quality or are considered by the Fund's investment adviser to be of comparable quality, at the time of investment.